We are seeking a #postdoc to understand #Bcells and identify related biomarkers of response in #lupus- 3 year post DoM_UCL funded by Versus Arthritis in collaboration with Dr Louisa James muhammad shipa Closing date 3 June. UK B cell Group tinyurl.com/2z4334yb

Very proud of my two clinical fellows who are giving talks at #EULAR2022. Su-Ann Yeoh tomorrow at 4.30 about #rheumatoid arthritis and muhammad shipa on #lupus and biomarkers from the BEAT-lupus trial on Friday at 10.30.

DoM Seminar: Dr Edward Vital (Virtual Seminar) Thursday 17th November, 2pm-3pm UCL DoM Early Careers UCL Faculty of Medical Sciences Michael Ehrenstein ucl.ac.uk/medicine/event…

Could a simple blood test, IgA2 anti-dsDNA antibodies, identify #lupus patients who will respond to #belimumab after #rituximab therapy? Biomarker analyses of the BEAT-lupus trial. muhammad shipa Liliana Ribeiro dos Santos Versus Arthritis GSK NIHR UCLH Biomedical Research Centre authors.elsevier.com/sd/article/S26…

NEW RESEARCH—In an exploratory analysis of the BEAT-LUPUS RCT muhammad shipa and colleagues examine biomarkers for response to B-cell-targeted therapies in systemic lupus erythematosus thelancet.com/journals/lanrh… Michael Ehrenstein Versus Arthritis LUPUSUK 💙 #OpenAccess

Our January issue is live! Including #psoriatic arthritis, systemic #lupus erythematosus, #vaccines, plus much more! thelancet.com/journals/lanrh… And introducing our cover artist for 2023, Grace Russell (Grace Russell)

Quest for the holy grail: #biomarkers in #SLE Read our January editorial thelancet.com/journals/lanrh…

Platinum Jubilee Chairs in rheumatology don’t come round very often. Closing date in 2 weeks. ⁦UCL⁩ ⁦UCL Faculty of Medical Sciences⁩ ucl.ac.uk/work-at-ucl/se…

Looking forward to #BSR23 next week 😃. We’ll have 3 x fantastic talks in the #lupus session. Hope to see you all there in person or virtually Rheumatology & Rheumatology Advances in Practice BSR Michael Ehrenstein Ed Vital

.muhammad shipa presents an exploratory biomarker analysis of response to belimumab after rituximab from the BEAT-Lupus trial; baseline serum IgA2 anti-dsDNA and type 2 double neg memory B cells predict response #BSR23 #SLE Michael Ehrenstein See paper: thelancet.com/journals/lanrh…

How experimental medicine can solve the challenge of modest efficacy and high cost drugs so that #lupus patients can access new treatments. ⁦muhammad shipa⁩ ⁦Versus Arthritis⁩ | Journal of Experimental Medicine | Rockefeller University Press rupress.org/jem/article/22…

Andrew Pollard nails it again: The UK's NHS has transformed healthcare by training clinical research leaders, but they must have protected time to deliver. This cannot be achieved while doctors and nurses are drowning in a chronically understaffed system. theguardian.com/commentisfree/…

Clinical trials provide a unique substrate to understand pathogenesis and identify biomarkers to targeted therapies in #SLE which can be used to stratify patients. Taken from a new Viewpoint by Michael Ehrenstein ⁦and ⁦⁦muhammad shipa⁩: rupress.org/jem/article/22…

Well done ⁦muhammad shipa⁩ for the nomination from Department of Inflammation for the ⁦DoM_UCL⁩ research award. Good luck! ucl.ac.uk/medicine/news-…

Very proud of muhammad shipa who successfully defended his thesis this afternoon. Well done! Thanks to Versus Arthritis and LUPUSUK 💙 for supporting his research.

Academic clinician–scientists risk becoming an endangered species. World View from stephen o'rahilly (its pronounced O-RA-hill-EEE) Cambridge University nature.com/articles/s4159…

Important research from John Reynolds and colleagues highlighting the differences in management approaches for #lupus nephritis within the UK and that rituximab remains the most popular choice for refractory renal disease academic.oup.com/rheumap/articl…